Prevention of Bacteremias Caused by α-Hemolytic Streptococci by Roxithromycin in Patients Treated with Intensive Cytotoxic Treatment

  • A. W. Dekker
  • M. Rozenberg-Arska
  • L. F. Verdonck
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)

Abstract

Microorganisms that frequently cause infections in patients with severe and prolonged granulocytopenia are endogenous gramnegative bacilli belonging to the normal flora of the alimentary tract [1]. Patients treated with cytotoxic drugs with a high degree of mucosal toxicity such as amsacrine and high-dose cytosine arabinoside or conditioning regimens for bone marrow transplantation are at high risk for bacteremias caused by α-hemolytic streptococci, microorganisms not commonly recognized as opportunistic pathogens [2–5]. We have shown that ciprofloxacin is highly effective in prevention of infection as well as colonization by gram-negative bacilli in granulocytopenic patients [6, 7]. However, infections caused by gram-positive bacteria, especially a-hemolytic streptococci and Staphylococcus epidermidis (often associated with the presence of indwelling catheters), have remained a problem. In the present study we added oral roxithromycin [8], a well-absorbed macrolide, to our prophylactic regimen during the granulocytopenic days with the highest degree of mucosal damage.

Keywords

Catheter Leukemia Bacillus Cyclophosphamide Candida 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH (1972) Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann Intern Med 77: 707–714PubMedGoogle Scholar
  2. 2.
    Cohen J, Donnelly JP, Worsley AM, Catovsky D, Goldman JM, Galton DAG (1983) Septicemia caused by viridans streptococci in neutropenic patients with leukemia. Lancet 11: 1452–1454CrossRefGoogle Scholar
  3. 3.
    Peters WG, Willemze R, Colly LP (1988) Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukemia. Eur J Hematol 40: 198–204CrossRefGoogle Scholar
  4. 4.
    Kern W, Kurrle E, Vanek E (1987) High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia. Klin Wochenschr 65: 773–780PubMedCrossRefGoogle Scholar
  5. 5.
    Steiner M, Villablanca J, Kersey J, Ramsay N, Ferrier M, Haake R, Weisdorf D (1988) a-Streptococcal shock in bone marrow transplantation patients. Blood 72 [Suppl l]:409a (Abstract 1548)Google Scholar
  6. 6.
    Dekker AW, Rozenberg-Arska M, Verhoef J (1987) Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 106: 7–12PubMedGoogle Scholar
  7. 7.
    Rozenberg-Arska M, Dekker AW, Verhoef J (1985) Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis 153: 104–107CrossRefGoogle Scholar
  8. 8.
    Rolston KV, Le Blanc B, Ho DH (1986) In vitro activity of RU 28965, a new macrolide compared to that of erythromycin. J Antimicrob Chemother 17: 161–163PubMedCrossRefGoogle Scholar
  9. 9.
    Dekker AW, Rozenberg-Arska M, Sixma J J, Verhoef J (1981) Prevention of infection by trimethoprim-sulfomethoxazole plus ampho 553 tericin B in patients with acute nonlymphocytic leukemia. Ann Intern Med 95: 555–559PubMedGoogle Scholar
  10. 10.
    Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE (1986) Norfloxacin versus Vancomycin/ Polymyxin for prevention of infections in granulocytopenic patients. Am J Med 80: 884–889PubMedCrossRefGoogle Scholar
  11. 11.
    Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlett JG, Sarai R, Burke PJ (1986) Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized double blind, placebo-controlled trial. Ann Intern Med 106: 1–7Google Scholar
  12. 12.
    Kern W, Kurrle E, Vanek E (1987) Ofloxacin for prevention of bacterial infections in granulocytopenic patients. Infection 15: 427–433PubMedCrossRefGoogle Scholar
  13. 13.
    Henslee J, Bostrom B, Weidsdorf D, Ramsay N, McGlave P, Kersey J (1984) Streptococcal sepsis in bone marrow transplant patients. Lancet 1: 393 (letter)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. W. Dekker
    • 1
  • M. Rozenberg-Arska
    • 2
  • L. F. Verdonck
    • 1
  1. 1.Departments of HematologyUniversity Hospital UtrechtUtrechtThe Netherlands
  2. 2.Clinical MicrobiologyUniversity Hospital UtrechtUtrechtThe Netherlands

Personalised recommendations